Sunitinib versus sorafenib as first-line therapy for patients with metastatic renal cell carcinoma with favorable or intermediate MSKCC risk factors: A multicenter randomized trial, CROSS-J-RCC.
Yoshihiko Tomita
Consultant or Advisory Role - Pfizer
Honoraria - Bayer; Pfizer
Research Funding - Bayer; Pfizer
Sei Naito
Honoraria - Pfizer
Naoto Sassa
Honoraria - Bayer; Pfizer
Atsushi Takahashi
Honoraria - Bayer; Pfizer
Tsunenori Kondo
Honoraria - Bayer; Pfizer
Takuya Koie
No relevant relationships to disclose
Wataru Obara
Honoraria - Bayer; Pfizer
Yasuyuki Kobayashi
No relevant relationships to disclose
Jun Teishima
No relevant relationships to disclose
Masayuki Takahashi
Honoraria - Bayer; Pfizer
Hideyasu Matsuyama
Honoraria - Bayer; Pfizer
Takeshi Ueda
Honoraria - Bayer; Pfizer
Kenya Yamaguchi
Honoraria - Pfizer
Ken Kishida
Honoraria - Bayer; Pfizer
Ryoichi Shiroki
Honoraria - Bayer; Pfizer
Takashi Saika
Honoraria - Bayer; Pfizer
Shinohara Nobuo
Consultant or Advisory Role - Bayer; Pfizer
Honoraria - Bayer; Pfizer
Mototsugu Oya
Consultant or Advisory Role - Bayer; Pfizer
Honoraria - Bayer; Pfizer
Hiro-Omi Kanayama
Consultant or Advisory Role - Bayer; Pfizer
Honoraria - Bayer; Pfizer